Search

Your search keyword '"Waksman R"' showing total 163 results

Search Constraints

Start Over You searched for: Author "Waksman R" Remove constraint Author: "Waksman R" Topic coronary restenosis Remove constraint Topic: coronary restenosis
163 results on '"Waksman R"'

Search Results

1. Myths and Truths in the Management of Drug-Eluting Stent In-Stent Restenosis.

2. Noncompliant Balloon Shaft Rupture Resulting in Ascending Aortic Dissection: Complication During Percutaneous Coronary Intervention.

3. A prospective, multicentre first-in-man study of the polymer-free ultrathin-strut BIOrapid stent (BIOVITESSE).

4. Waksman In-Stent Restenosis Classification: A Mechanism-Based Approach to the Treatment of Restenosis.

5. Impact of intravascular ultrasound on Outcomes following PErcutaneous coronary interventioN for In-stent Restenosis (iOPEN-ISR study).

6. One-Year Outcomes After Treatment of Ostial In-Stent Restenosis in Left Circumflex Versus Left Anterior Descending or Right Coronary Artery.

7. Cases of Early, Aggressive In-Stent Restenosis in Left Main Double Kissing (DK) Crush Technique and Treatment Options.

8. Detachment of an EluNIR Drug-Eluting Stent Spring Tip.

9. Treatment of Patients With Recurrent Coronary In-stent Restenosis With Failed Intravascular Brachytherapy.

10. Trends and Outcomes of Restenosis After Coronary Stent Implantation in the United States.

13. Combined Vascular Brachytherapy and Stenting for the Treatment of In-Stent Restenosis.

14. Restenosis of Drug-Eluting Stents: A New Classification System Based on Disease Mechanism to Guide Treatment and State-of-the-Art Review.

15. Refractory In-Stent Restenosis: Improving Outcomes by Standardizing Our Approach.

16. In-Stent Restenosis of Drug-Eluting Stents Compared With a Matched Group of Patients With De Novo Coronary Artery Stenosis.

17. A new generation of drug-eluting stents: Indications and outcomes of bioresorbable vascular scaffolds.

19. Intracoronary Brachytherapy for Recurrent Drug-Eluting Stent Failure.

20. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial.

21. Comparison of clinical outcomes in patients presenting with an acute coronary syndrome due to stent thrombosis or saphenous vein graft occlusion and undergoing percutaneous coronary intervention.

22. Safety and efficacy of everolimus-eluting stents for bare-metal in-stent restenosis.

23. Safety and efficacy of limus-eluting stents and balloon angioplasty for sirolimus-eluting in-stent restenosis.

24. Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial.

25. Long-term safety and efficacy of second-generation everolimus-eluting stents compared to other limus-eluting stents and bare metal stents in patients with acute coronary syndrome.

26. Current application and bioavailability of drug-eluting stents.

27. Paclitaxel-coated balloon for the treatment of drug-eluting stent restenosis: subanalysis results from the Valentines I trial.

28. Acute closure after stenting: not always a thrombus.

29. In-stent restenosis of drug-eluting stents.

30. Drug-coated balloons for de novo coronary lesions: results from the Valentines II trial.

31. Optimal revascularization strategies for percutaneous coronary intervention of distal anastomotic lesions after coronary artery bypass surgery.

33. Utilization of intravascular ultrasound to accurately position stents in true aorto-ostial lesions.

34. Paclitaxel drug-coated balloons: a review of current status and emerging applications in native coronary artery de novo lesions.

35. Too early to call.

36. Clinical outcomes and treatment after drug-eluting stent failure: the absence of traditional risk factors for in-stent restenosis.

37. The Valentines Trial: results of the first one week worldwide multicentre enrolment trial, evaluating the real world usage of the second generation DIOR paclitaxel drug-eluting balloon for in-stent restenosis treatment.

38. Saphenous vein graft intervention.

39. Outcomes of patients with acute myocardial infarction from a saphenous vein graft culprit undergoing percutaneous coronary intervention.

40. A novel approach for a clinical trial based on a cardiology meeting.

42. Sirolimus-eluting stents versus paclitaxel-eluting stents in patients with chronic renal insufficiency.

43. Drug-eluting stents: issues of late stent thrombosis.

44. Outcome of undersized drug-eluting stents for percutaneous coronary intervention of saphenous vein graft lesions.

45. Drug-eluting balloon: the comeback kid?

46. Clinical manifestation and prognosis of early versus late stent thrombosis of drug-eluting stents.

47. Impact of thrombus aspiration use for the treatment of stent thrombosis on early patient outcomes.

48. A critical appraisal of the safety and efficacy of drug-eluting stents.

49. Incidence, predictors, and outcome of new, subsequent lesions treated with percutaneous coronary intervention in patients presenting with myocardial infarction.

50. Requirement for emergent coronary artery bypass surgery following percutaneous coronary intervention in the stent era.

Catalog

Books, media, physical & digital resources